Seeking Alpha

Seeking Alpha Portfolio App for iPad

430 people get SLXP articles and Market Currents by email alert.

Get email alerts on SLXP »

SLXP

Salix Pharmaceuticals, Ltd.

5/25/2013, 12:54 PM ET

Quote & Headlines Market Currents StockTalk

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, August 8, 2012, 5:28 PM Salix Pharmaceuticals (SLXP): Q2 EPS of $0.79 beats by $0.25. Revenue of $181M (+36% Y/Y) in-line. Shares +9.4% AH. (PR) Comment! [Earnings, Healthcare, On the Move]
Monday, August 6, 2012, 3:38 PM Salix Pharmaceutica (SLXP -0.3%) gets a Paragraph VI Patent certification for its ulcerative colitis treatment Apriso. Comment! [Healthcare]
Monday, July 30, 2012, 9:10 AM Premarket gainers: SHAW +65%. CDTI +60%. VRML +14%. ATPG +11%. OCZ +11%. BBY +8%. EXEL +5%. ACI +5%. MDR +5%.
Losers: PGNX -44%. SLXP -12%. STP -11%. CBI -10%. Comment! [On the Move]
Monday, July 30, 2012, 8:57 AM Salix Pharmaceuticals (SLXP) -10.7% and Progenics Pharmaceuticals (PGNX) -47% after saying late on Friday that the FDA has asked for more data on their Relistor drug for patients who have become constipated from taking opioids to treat chronic non-cancer pain. Comment! [Healthcare, On the Move]
Thursday, May 31, 2012, 2:30 PM AstraZeneca (AZN -0.1%) will appoint a new CEO over the next six months and the person should be aggressive on acquisitions, according to Leerink Swann. Leerink views Forest Labs (FRX +3.5%), a stock it upgraded this morning to Outperform, as the most logical takeover target for AZN, but also feels the company has several other options, including Amylin (AMLN -2.7%) and Salix (SLXP -0.1%). Comment! [Healthcare]
Monday, May 7, 2012, 5:16 PM Salix Pharmaceuticals (SLXP): Q1 EPS of $0.67 beats by $0.11. Revenue of $171.1M (+62% Y/Y). (PR) Comment! [Earnings, Healthcare]
Tuesday, April 10, 2012, 11:20 AM Salix Pharmaceuticals (SLXP -4.8%) slides after Auriga downgrades the stock to Hold from Buy and lowers its price target to $51 from $54. The firm says SLXP shares appear to have already priced in upside from the potential approval of developmental drugs Relistor and Crofelemer. Auriga had upgraded shares to Buy only six weeks ago. Comment! [Healthcare, On the Move]
Tuesday, February 28, 2012, 12:24 PM Salix Pharmaceuticals (SLXP +7.1%) spikes higher on volume 3X normal trading activity after Auriga upgrades it to a Buy rating with a $54 price target. Analysts call the firm's 2012 guidance conservative and indicate that they see a high likelihood that Salix will outperform. Comment! [Healthcare, On the Move]
Tuesday, February 28, 2012, 11:49 AM Salix Pharmaceuticals (SLXP +7.3%) shares surge after Q4 results topped expectations and sales of its Xifaxan gastrointestinal drug picked up significantly during H2 2011. SLXP also guides to at least 25% organic growth in Xifaxan in 2012, with strong growth in January that beat the prior record month of December. Comment! [Healthcare, On the Move]
Monday, February 27, 2012, 4:13 PM Salix Pharmaceuticals (SLXP): Q4 EPS of $1.18 beats by $0.24. Revenue of $155.1M (+31% Y/Y) beats by $3M. (PR) Comment! [Earnings, Healthcare]
Monday, February 27, 2012, 12:10 AM Notable earnings after Monday's close: AWK, CVI, GXP, HGSI, JAZZ, MR, PCLN, SINA, SLXP, SWN, UHS, URS, VNO, WES Comment! [Earnings]
Sunday, February 26, 2012, 5:35 PM Notable earnings after Monday's close: AWK, CVI, GXP, HGSI, JAZZ, MR, PCLN, SINA, SLXP, SWN, UHS, URS, VNO, WES Comment! [Earnings]
Friday, February 10, 2012, 11:02 AM Salix Pharmaceuticals (SLXP -7.7%) plunges after the FDA provides relatively lenient clinical study guidelines (.pdf) for would-be makers of a generic version of Salix's Xifaxan drug. Salix closed yesterday near its 52-week high. Comment! [Healthcare, On the Move]
Friday, January 20, 2012, 3:29 PM Salix Pharmaceuticals (SLXP -5%) lags the market today after Stifel Nicolaus cut the shares to Hold on valuation, noting it doesn't expect any significant outperformance from the stock, given an already impressive move coming out of 2011. Comment!
Tuesday, December 20, 2011, 9:05 AM Premarket gainers: CSIQ +27%. PGNX +26%. AIS +17%. SLXP +11%. S +7%. CLWR +7%. JEF +6%. ALU +6%. NOK +5%. DB +5%. RIO +5%. MT +4%. STD +4%. BBVA +4%. STM +4%. VHC +4%. GSS +4%. ANR +4%. MS +4%. ERIC +4%. BHP +3%. ZMH +3%. VALE +3%. ITUB +3%. SNE +3%. C +3%. VE +3%. X +3%. MU +3%. HAL +3%. SI +3%.
Losers: TRGT -22%. RHT -8%. GFA -4%. Comment! [On the Move]
Tuesday, December 20, 2011, 8:45 AM Salix Pharmaceuticals (SLXP) and Progenics (PGNX) report "positive" highly statistically significant results of the Phase 3 of oral methylnaltrexone for the treatment of opioid-induced constipation in subjects with chronic, non-cancer pain. SLXP +11%, PGNX +18.8% premarket. (PR) Comment! [Healthcare, On the Move]